Multicentric experience with combined hemodialysis/hemoperfusion in chronic uremia.
A multicentric study was carried out to investigate the safety and effectiveness of long-term treatment of chronic uremic patients by a regular combination of hemodialysis and charcoal hemoperfusion. 39 RDT patients from five dialysis centers were treated for up to 12 months. The combined treatment proved to be safe, well tolerated and effective in improving certain dialysis-resistant uremic signs, mainly severe peripheral neuropathy, asthenia, anorexia, nausea, lack of well-being and relapsing pericarditis. There was also a marked decrease, after several weeks of combined treatment, in plasma values of urea, uric acid and creatinine.
D000328:Adult; D001806:Blood Urea Nitrogen; D002606:Charcoal / Q000627:therapeutic use; D002908:Chronic Disease; D003404:Creatinine / Q000097:blood; D005260:Female; D006464:Hemoperfusion / Q000009:adverse effects; D006801:Humans; D008297:Male; D008689:Methacrylates / Q000627:therapeutic use; D008875:Middle Aged; D009431:Neural Conduction / Q000187:drug effects; D006435:Renal Dialysis / Q000009:adverse effects; D014511:Uremia / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D014527:Uric Acid / Q000097:blood
D008689:Methacrylates; D002606:Charcoal; D014527:Uric Acid; D003404:Creatinine